Progenics Pharmaceuticals, Inc.
One World Trade Center
New York, New York 10007
January 18, 2017
Via EDGAR
Johnny Gharib
Senior Counsel
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549-3561
Re: | Progenics Pharmaceuticals, Inc. |
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-215454) (the “Registration Statement”) be accelerated by the Securities and Exchange Commission (the “Commission”) so that the Registration Statement will become effective at 4:30 p.m., Eastern Daylight Time, on January 19, 2017, or as soon as practicable thereafter.
Please do not hesitate to contact Tobias L. Knapp, Esq. of O’Melveny & Myers LLP at (212) 408-2440 with any questions or comments with respect to this letter.
Very truly yours, |
